Dr Mols is a Belgian citizen currently working in R&D for GSK Vaccines in Rixensart, Belgium. Dr Mols holds Master degrees in both Chemistry and Biology from the UCL (Université Catholique de Louvain; Louvain-la-Neuve). Dr Mols received his PhD degree from UCL, in 2004, studying proteolytic degradation and glycosylation pathways for recombinant glycoprotein secreted from high density suspension of CHO cells in bioreactors. Additionally, he was trained as a postdoctoral fellow at the Scripps Research Institute in La Jolla, San Diego, CA. His research focused on the role of RNA interference and miRNA on mRNA stability and repression of translational initiation for cytokine mRNAs in the context of inflammation. In 2007, Dr Mols joined GSK Vaccines R&D, in Rixensart, where he held various R&D roles of increasing responsibilities. Since 2009 he has led the development of multiple vaccine candidates: i.e. Shingrix, CMV, C difficile, HSV, HPV but also of antigen specific immunotherapies for chronic infectious diseases and cancer. In 2018, he graduated from HEC Paris with an executive MBA and is currently acting Vaccine Development Leader for GSK’s HSV-specific immunotherapy, currently in ph1/2, and as scientific advisor for the COVID pandemic trajectory.